Dr. Chris Longenecker discusses the REPRIEVE trial, a study of pitavastatin versus placebo for persons with HIV with low-to-moderate risk of ischemic cardiovascular disease, and gives his perspective on whether the study results should change versus affirm current practice.
6 фев 2024